{"product_id":"low-risk-thyroid-cancer-why-japanese-doctors-often-choose-less-aggressive-surgery","title":"Low-Risk Thyroid Cancer: Why Japanese Doctors Often Choose Less Aggressive Surgery","description":"\u003cp\u003eThis review article from Kanaji Thyroid Hospital in Tokyo explains why Japanese doctors often treat low-risk thyroid cancer differently than their Western counterparts. Instead of routinely removing the entire thyroid gland followed by radioactive iodine treatment, Japanese surgeons frequently use more limited surgery (removing only part of the thyroid) to preserve quality of life for patients with low-risk disease. The article shares data from 1,411 patients treated at the hospital between 1993 and 2012, along with a detailed comparison of international treatment guidelines for both papillary and follicular thyroid cancers. While no single approach fits every patient, the key message is that many low-risk patients can safely avoid aggressive treatment.\u003c\/p\u003e\n\n\u003ch1\u003eLow-Risk Thyroid Cancer: Why Japanese Doctors Often Choose Less Aggressive Surgery\u003c\/h1\u003e\n\n\u003ch2\u003eTable of Contents\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\u003ca href=\"#ddn-key-points\"\u003eKey Points\u003c\/a\u003e\u003c\/li\u003e\n\n  \u003cli\u003e\u003ca href=\"#background\"\u003eUnderstanding Thyroid Cancer and Why This Research Matters\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#incidence\"\u003eHow Common Is Thyroid Cancer? The Numbers Behind the Disease\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#differences\"\u003eWhy Treatment Differs Between Japan and Western Countries\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#study-methods\"\u003eAbout the Study: Two Decades of Data from Kanaji Thyroid Hospital\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#low-risk-papillary\"\u003eTreatment for Low-Risk Papillary Thyroid Cancer\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#surgery-options\"\u003eSurgical Options: How Much of the Thyroid Should Be Removed?\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#lymph-nodes\"\u003eLymph Node Dissection: A Key Difference in Practice\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#observation\"\u003eTo Operate or Not? The Observation Debate for Tiny Cancers\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#low-risk-follicular\"\u003eTreatment for Low-Risk Follicular Thyroid Cancer\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#rai\"\u003eRadioactive Iodine Ablation and TSH Suppression: Risks and Benefits\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#clinical-implications\"\u003eWhat This Means for Patients\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#limitations\"\u003eStudy Limitations: What This Review Cannot Prove\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#recommendations\"\u003eRecommendations for Patients\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#ddn-faq\"\u003eFrequently Asked Questions\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#source\"\u003eSource Information\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003c!-- ddn:keypoints:start --\u003e\n\u003ch2 id=\"ddn-key-points\"\u003eKey Points\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003eIn the US, thyroid cancer incidence rose 2.4-fold from 1973 to 2002, but mortality stayed stable.\u003c\/li\u003e\n\u003cli\u003eJapanese data from one hospital: recurrence in remaining thyroid after hemi-thyroidectomy for low-risk papillary cancer was only 1%.\u003c\/li\u003e\n\u003cli\u003eTotal thyroidectomy does not reduce lymph node or distant recurrence compared with hemi-thyroidectomy.\u003c\/li\u003e\n\u003cli\u003eFor low-risk papillary micro-carcinoma under 1 cm, observation may be an option instead of immediate surgery.\u003c\/li\u003e\n\u003cli\u003eWestern and Japanese treatment guidelines are converging: RAI ablation is questioned for low-risk patients, and total thyroidectomy is accepted for high-risk patients.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c!-- ddn:keypoints:end --\u003e\n\n\n\u003ch2 id=\"background\"\u003eUnderstanding Thyroid Cancer and Why This Research Matters\u003c\/h2\u003e\n\n\u003cp\u003eThyroid cancer is a disease in which malignant (cancerous) cells form in the tissues of the thyroid gland, a butterfly-shaped organ located in the front of the neck that produces hormones regulating metabolism. The good news is that the most common form, \u003cstrong\u003edifferentiated thyroid carcinoma (DTC)\u003c\/strong\u003e, tends to grow very slowly and has a far more favorable prognosis compared with many other types of cancer.\u003c\/p\u003e\n\n\u003cp\u003eThis review focuses on a long-standing debate: how aggressively should doctors treat low-risk thyroid cancer? In Western countries, the standard approach has been \u003cstrong\u003etotal thyroidectomy\u003c\/strong\u003e (removal of the entire thyroid gland), followed by \u003cstrong\u003eradioactive iodine (RAI) ablation\u003c\/strong\u003e — a treatment that uses radioactive iodine to destroy any remaining thyroid tissue or cancer cells. In Japan, however, a very different philosophy has taken hold.\u003c\/p\u003e\n\n\u003cp\u003eJapanese surgeons have extensively adopted \u003cstrong\u003ehemi-thyroidectomy\u003c\/strong\u003e (removal of half of the thyroid) and \u003cstrong\u003esubtotal thyroidectomy\u003c\/strong\u003e (removal of most, but not all, of the thyroid). This difference matters because it affects patients' quality of life, the need for lifelong medication, and the risk of surgical complications.\u003c\/p\u003e\n\n\u003cp\u003eImportantly, the authors note that \u003cstrong\u003epapillary thyroid carcinoma (PTC)\u003c\/strong\u003e accounts for over 90% of all thyroid cancers in Japan. The majority of these patients fall into a \"low-risk\" category under modern risk-classification systems, and they show excellent outcomes regardless of how aggressive the initial treatment is.\u003c\/p\u003e\n\n\u003ch2 id=\"incidence\"\u003eHow Common Is Thyroid Cancer? The Numbers Behind the Disease\u003c\/h2\u003e\n\n\u003cp\u003eThe article provides striking data on how thyroid cancer rates are changing. In the United States, the incidence of thyroid cancer increased from \u003cstrong\u003e3.6 per 100,000 people in 1973 to 8.7 per 100,000 in 2002\u003c\/strong\u003e — a 2.4-fold increase, according to research by Davies and Gilbert Welch using Surveillance, Epidemiology, and End Results (SEER) program data. During the same period, however, thyroid cancer mortality remained stable, suggesting that much of the increase was due to detecting small, otherwise harmless cancers rather than a true epidemic of deadly disease.\u003c\/p\u003e\n\n\u003cp\u003eVirtually all of this increase in the US was due to papillary carcinoma specifically, which rose from \u003cstrong\u003e2.7 to 7.7 per 100,000\u003c\/strong\u003e — representing a \u003cstrong\u003e2.9-fold increase\u003c\/strong\u003e. The rates of follicular, medullary, and anaplastic carcinoma — the less common types — did not change significantly.\u003c\/p\u003e\n\n\u003cp\u003eIn Japan, the picture is somewhat different. In 2003, the incidence of thyroid carcinoma in males was \u003cstrong\u003e3.25 per 100,000\u003c\/strong\u003e and in females it was \u003cstrong\u003e9.26 per 100,000\u003c\/strong\u003e. The age-adjusted incidence was \u003cstrong\u003e2.56 per 100,000 for males and 7.17 per 100,000 for females\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003eLooking at the breakdown of cancer types, data from the Japanese Society of Thyroid Surgeons (JSTS) in 2004 (with Kanaji Thyroid Hospital's own figures shown in parentheses) found:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003ePapillary carcinoma: \u003cstrong\u003e92.5%\u003c\/strong\u003e of cases (92.0% at Kanaji)\u003c\/li\u003e\n  \u003cli\u003eFollicular carcinoma: \u003cstrong\u003e4.8%\u003c\/strong\u003e (5.9% at Kanaji)\u003c\/li\u003e\n  \u003cli\u003eMedullary carcinoma: \u003cstrong\u003e1.3%\u003c\/strong\u003e (1.0% at Kanaji)\u003c\/li\u003e\n  \u003cli\u003eAnaplastic carcinoma: \u003cstrong\u003e1.4%\u003c\/strong\u003e (1.2% at Kanaji)\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThe authors note that Japan is a \"world-prominent iodine-sufficient country,\" and suggest that the sufficient dietary intake of iodine — largely from seaweed and seafood — may partially explain why papillary carcinoma rates differ between Japan and Western countries.\u003c\/p\u003e\n\n\u003ch2 id=\"differences\"\u003eWhy Treatment Differs Between Japan and Western Countries\u003c\/h2\u003e\n\n\u003cp\u003eThe treatment of differentiated thyroid cancer in Japan has traditionally followed a different path than in the West. In the United States and Europe, total or near-total thyroidectomy is performed almost routinely, followed by RAI ablation and \u003cstrong\u003ethyroid-stimulating hormone (TSH) suppression therapy\u003c\/strong\u003e — giving patients thyroid hormone medication at doses high enough to keep TSH levels low, since TSH can stimulate any remaining thyroid cancer cells.\u003c\/p\u003e\n\n\u003cp\u003eJapanese surgeons, by contrast, were slower to adopt this aggressive approach for several practical, cultural, and medical reasons:\u003c\/p\u003e\n\n\u003col\u003e\n  \u003cli\u003e\n\u003cstrong\u003eLimited access to RAI:\u003c\/strong\u003e Strict legal restrictions in Japan limited the number of hospitals able to administer radioactive iodine. Only patients with very advanced cancer could undergo RAI ablation.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eClinical experience:\u003c\/strong\u003e Japanese endocrine surgeons observed that most differentiated thyroid cancers are indolent (slow-growing) and show excellent prognosis even without total thyroidectomy, RAI ablation, or TSH suppression.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eComplication avoidance:\u003c\/strong\u003e Limited thyroidectomy reduces the risk of severe complications, such as \u003cstrong\u003ebilateral recurrent-laryngeal nerve palsy\u003c\/strong\u003e (paralysis of both vocal cords) and \u003cstrong\u003eirreversible hypoparathyroidism\u003c\/strong\u003e (damage to the parathyroid glands, causing dangerously low calcium levels). It may also mean patients do not need to take \u003cstrong\u003eL-thyroxine\u003c\/strong\u003e (thyroid hormone replacement) for life.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eDifferent surveillance model:\u003c\/strong\u003e Postoperative surveillance in Japan is conducted by surgeons themselves and makes extensive use of nationwide ultrasonography, which is routine and affordable — unlike in Western countries, where ultrasound is more exclusive and expensive.\u003c\/li\u003e\n\u003c\/ol\u003e\n\n\u003cp\u003eThe table below summarizes these socio-medical differences between Japan and Western countries:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eIodine status:\u003c\/strong\u003e Japan is a world-leading iodine-sufficient country, while many Western countries are in iodine-deficient areas\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eWho follows patients:\u003c\/strong\u003e Japanese surgeons conduct their own postoperative surveillance; Western patients are generally followed by internists or radiologists\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eRAI availability:\u003c\/strong\u003e Japan has strict legal restrictions and limited infrastructure for RAI; in the West, total thyroidectomy plus RAI ablation is standard\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eUltrasound access:\u003c\/strong\u003e Japan uses ultrasonography nationwide as a routine tool; in Western countries, it remains an exclusive and expensive procedure\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2 id=\"study-methods\"\u003eAbout the Study: Two Decades of Data from Kanaji Thyroid Hospital\u003c\/h2\u003e\n\n\u003cp\u003eThis is a \u003cstrong\u003ereview article\u003c\/strong\u003e, meaning it combines the authors' clinical experience with an analysis of published medical literature and international guidelines. The clinical data comes from \u003cstrong\u003eKanaji Thyroid Hospital in Tokyo, Japan\u003c\/strong\u003e, a specialized center with unusually extensive experience in treating this disease.\u003c\/p\u003e\n\n\u003cp\u003eBetween \u003cstrong\u003e1993 and 2012\u003c\/strong\u003e, a total of \u003cstrong\u003e4,560 patients\u003c\/strong\u003e with thyroid and parathyroid disease underwent surgical treatment at the hospital. Among them, \u003cstrong\u003e1,411 patients\u003c\/strong\u003e with differentiated thyroid carcinoma underwent thyroidectomy and lymph node dissection. Distant metastases (cancer spread to other organs) appeared in \u003cstrong\u003e100 cases\u003c\/strong\u003e — including 83 papillary thyroid cancers and 17 follicular thyroid cancers. Of these, there were \u003cstrong\u003e70 lung metastases and 30 bone and\/or lung metastases\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003eSince \u003cstrong\u003e2005\u003c\/strong\u003e, the hospital has performed RAI therapy aggressively for patients with distant metastases and high-risk differentiated thyroid cancer. This is notable because it represents a rare situation in Japan, where most institutions have limited RAI capacity.\u003c\/p\u003e\n\n\u003cp\u003eThe authors also compared treatment guidelines from five major medical organizations — the National Comprehensive Cancer Network (NCCN), American Thyroid Association (ATA), British Thyroid Association (BTA), American Association of Clinical Endocrinologists\/American Association of Endocrine Surgeons (AACE\/AAES), and the Japanese Society of Thyroid Surgery\/Japan Association of Endocrine Surgeons (JSTS\/JAES) — against their own institutional practice at Kanaji Thyroid Hospital (established in 2010).\u003c\/p\u003e\n\n\u003ch2 id=\"low-risk-papillary\"\u003eTreatment for Low-Risk Papillary Thyroid Cancer\u003c\/h2\u003e\n\n\u003cp\u003ePapillary and follicular cancers are grouped together as differentiated thyroid carcinoma, but they behave quite differently. \u003cstrong\u003ePapillary carcinoma\u003c\/strong\u003e tends to spread to lymph nodes in the neck. \u003cstrong\u003eFollicular carcinoma\u003c\/strong\u003e is more likely to spread to distant organs through the bloodstream. Because of these differences, the authors discuss treatment recommendations for each type separately.\u003c\/p\u003e\n\n\u003cp\u003eAt Kanaji Thyroid Hospital, the standard approach for low-risk papillary carcinoma is guided by two key classifications:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eHigh-risk patients\u003c\/strong\u003e are those with a maximum tumor diameter \u003cstrong\u003egreater than 5 cm\u003c\/strong\u003e, extrathyroid extension to the mucosa of the trachea (windpipe) or esophagus, a large number of clinical lymph node metastases, lymph node metastasis \u003cstrong\u003elarger than 3 cm\u003c\/strong\u003e, or the presence of distant metastasis. These patients are recommended to undergo total thyroidectomy.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eLow-risk patients\u003c\/strong\u003e are those with a maximum tumor diameter \u003cstrong\u003eless than 2 cm\u003c\/strong\u003e and no clinical lymph node metastasis — classified as \u003cstrong\u003eT1N0M0\u003c\/strong\u003e in the TNM staging system (T refers to tumor size, N to lymph node involvement, and M to distant metastasis). For these patients, \u003cstrong\u003ehemi-thyroidectomy is acceptable\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003ePatients who fall in between these categories are said to be in a \"gray zone.\" However, the majority of institutions worldwide encourage total thyroidectomy for tumors larger than 4 cm or when clinical lymph node metastases are present.\u003c\/p\u003e\n\n\u003ch2 id=\"surgery-options\"\u003eSurgical Options: How Much of the Thyroid Should Be Removed?\u003c\/h2\u003e\n\n\u003cp\u003eOne of the central controversies in thyroid cancer treatment is whether removing the entire thyroid improves survival compared with removing only part of it. The authors state plainly that there is \u003cstrong\u003einsufficient evidence\u003c\/strong\u003e to show that total thyroidectomy improves cause-specific survival relative to hemi-thyroidectomy in patients with papillary carcinoma.\u003c\/p\u003e\n\n\u003cp\u003eTotal thyroidectomy does prevent recurrence in the remaining (remnant) thyroid tissue, but importantly, \u003cstrong\u003eit does not reduce the incidence of recurrence in lymph nodes or distant metastasis\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003eWhat do the major guidelines say? The comparison is striking:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eATA guidelines (2006):\u003c\/strong\u003e Recommend total or near-total thyroidectomy for differentiated thyroid cancer, except for low-risk micro-papillary carcinoma (tumors smaller than 1 cm).\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eBTA guidelines (2007):\u003c\/strong\u003e Recommend total thyroidectomy for most papillary carcinomas, especially those with a tumor diameter greater than 1 cm, multifocal disease (cancer in multiple areas), extrathyroidal extension, familial disease, history of neck irradiation, or clinical lymph node metastases.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAACE\/AAES guidelines:\u003c\/strong\u003e Recommend total thyroidectomy for high-risk patients and for those with cancer in both lobes, nodules in the opposite lobe, extrathyroidal extension, or local\/distant metastasis.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eNCCN guidelines (2008):\u003c\/strong\u003e Accept hemi-thyroidectomy for patients with ALL of the following: age 15–45 years, no prior radiation treatment, no distant metastasis, no cervical lymph node metastasis, no extrathyroidal extension, tumors smaller than 4 cm, and no signs of aggressive variants. However, even these guidelines note that total thyroidectomy is the \"most common\" strategy.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eJSTS\/JAES guidelines (2011) and Kanaji Hospital (2010):\u003c\/strong\u003e Recommend total thyroidectomy for tumors larger than 2 cm (Kanaji) or 4 cm (JSTS\/JAES), extrathyroidal extension, lymph node metastasis, or distant metastasis. Allow lobectomy for tumors under 2 cm with no lymph node or distant metastasis.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThe authors point out an important weakness in Western studies claiming better outcomes with total thyroidectomy. Most patients who undergo total thyroidectomy in Western countries also receive RAI ablation therapy, meaning those studies may not have truly compared surgery alone versus surgery plus RAI. This makes it hard to know how much of the benefit comes from the surgery itself versus the radioactive iodine treatment.\u003c\/p\u003e\n\n\u003cp\u003eSeveral studies have actually \u003cstrong\u003efailed to demonstrate any effect\u003c\/strong\u003e of the extent of thyroidectomy on patient outcomes. Notably, a Japanese report found that the rate of recurrence in the remnant thyroid among patients with solitary T1N0M0 papillary carcinoma who underwent hemi-thyroidectomy was \u003cstrong\u003eonly 1%\u003c\/strong\u003e — an excellent prognosis when combined with elective lymph node dissection and no radioactive iodine therapy.\u003c\/p\u003e\n\n\u003cp\u003eTo understand the trade-offs, consider the merits and demerits of each surgical approach:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTotal thyroidectomy — benefits:\u003c\/strong\u003e Easier to perform radioactive iodine therapy afterward; virtually no risk of recurrence in remnant thyroid tissue.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTotal thyroidectomy — drawbacks:\u003c\/strong\u003e Postoperative hypothyroidism (patients must take thyroid hormone medication for life); risk of hypoparathyroidism (low calcium levels); risk of bilateral recurrent-laryngeal nerve paralysis (vocal cord damage).\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eLimited thyroidectomy — benefits:\u003c\/strong\u003e Low risk of postoperative hypothyroidism (possibly no medication needed); fewer serious complications.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eLimited thyroidectomy — drawbacks:\u003c\/strong\u003e Risk of recurrence in the remnant thyroid tissue; radioactive iodine therapy is more difficult to use if needed later.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2 id=\"lymph-nodes\"\u003eLymph Node Dissection: A Key Difference in Practice\u003c\/h2\u003e\n\n\u003cp\u003eSince papillary carcinoma most often recurs in lymph nodes, Japanese surgeons have historically performed \u003cstrong\u003eprophylactic lymph node dissection\u003c\/strong\u003e — removing lymph nodes that do not show visible signs of cancer — more actively than their Western colleagues. This includes dissecting not only the central compartment (the area immediately around the thyroid) but also the lateral compartment (the sides of the neck).\u003c\/p\u003e\n\n\u003cp\u003eThe evidence for this practice is debated. There is \u003cstrong\u003eno evidence that prophylactic central compartment dissection improves cause-specific survival\u003c\/strong\u003e for patients with papillary carcinoma. However, it does reduce the risk of relapse in lymph nodes and improves \u003cstrong\u003edisease-free survival\u003c\/strong\u003e (the length of time a patient lives without signs of cancer).\u003c\/p\u003e\n\n\u003cp\u003eGuideline recommendations vary considerably:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eATA:\u003c\/strong\u003e Prophylactic central node dissection may be performed for T3 or T4 tumors, but is not necessary for T1 or T2 tumors.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eBTA:\u003c\/strong\u003e Recommends prophylactic central node dissection only for patients with high-risk features: male gender, age \u0026gt;45 years, tumor diameter \u0026gt;4 cm, or extrathyroidal disease.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eNCCN:\u003c\/strong\u003e Suggests considering it for patients with one or more of: age \u0026lt;15 or \u0026gt;45 years, history of radiation therapy, known distant metastases, bilateral nodularity, extrathyroidal extension, tumor \u0026gt;4 cm, or aggressive variants.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAACE\/AAES:\u003c\/strong\u003e Does not recommend prophylactic central node dissection.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eJSTS\/JAES:\u003c\/strong\u003e Notes there is currently insufficient evidence that central node dissection improves prognosis. However, because imaging often cannot detect central compartment metastasis, and reoperation for recurrence carries high risks of injury to the recurrent-laryngeal nerve and persistent hypoparathyroidism, the Kanaji authors conclude that prophylactic central compartment dissection \u003cstrong\u003eis\u003c\/strong\u003e of significance — a position in sharp contrast to Western guidelines.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThe authors also note that while there is no evidence that prophylactic \u003cstrong\u003elateral\u003c\/strong\u003e node dissection improves life expectancy, it reduces the risk of lymph node relapse. They recommend performing it during the \u003cstrong\u003einitial surgery\u003c\/strong\u003e, because reoperation in this area carries a serious risk of complications.\u003c\/p\u003e\n\n\u003ch2 id=\"observation\"\u003eTo Operate or Not? The Observation Debate for Tiny Cancers\u003c\/h2\u003e\n\n\u003cp\u003eOne of the most patient-relevant questions in thyroid cancer care is whether very small cancers even need surgery at all. The widespread use of ultrasound and ultrasound-guided \u003cstrong\u003efine-needle aspiration cytology (FNAC)\u003c\/strong\u003e — where a thin needle is used to sample cells from a nodule — has led to the detection of many small, low-risk papillary micro-carcinomas (tumors smaller than 1 cm).\u003c\/p\u003e\n\n\u003cp\u003eDavies and Welch's US data are highly relevant here: from 1973 to 2002, the incidence of thyroid carcinoma increased 2.4-fold, yet \u003cstrong\u003emortality remained stable\u003c\/strong\u003e. They concluded that this reflected increased detection of subclinical cases — small cancers that were never destined to cause harm.\u003c\/p\u003e\n\n\u003cp\u003eIn Japan, the incidence of incidentally detected thyroid carcinoma found during mass screening is reportedly \u003cstrong\u003e1,000-fold higher\u003c\/strong\u003e than the incidence of overt (symptomatic) carcinoma. This means many patients are being diagnosed with cancers that may never have caused problems.\u003c\/p\u003e\n\n\u003cp\u003eThe Kanaji Hospital approach is as follows:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSurgery is mandatory\u003c\/strong\u003e for patients with papillary micro-carcinoma who have clinical lymph node metastasis detectable by palpation or imaging, or who have distant metastasis or significant extrathyroidal extension.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eObservation (active surveillance) may be offered\u003c\/strong\u003e to patients without these features, after a thorough explanation of the situation and acquisition of informed consent.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThe authors emphasize that Japanese studies of low-risk and incidentally detected micro-papillary carcinoma show excellent outcomes, and they call for ongoing discussion about whether simple observation or thyroidectomy should be the standard strategy for these tiny cancers.\u003c\/p\u003e\n\n\u003ch2 id=\"low-risk-follicular\"\u003eTreatment for Low-Risk Follicular Thyroid Cancer\u003c\/h2\u003e\n\n\u003cp\u003eFollicular thyroid carcinoma presents a unique diagnostic challenge: unlike papillary cancer, it \u003cstrong\u003ecannot usually be diagnosed before surgery\u003c\/strong\u003e. Most follicular carcinomas are found only after the nodule has been removed and examined under a microscope in a postoperative pathological examination. Before surgery, patients are typically diagnosed with a \"follicular tumor\" or \"follicular neoplasm\" of undetermined significance.\u003c\/p\u003e\n\n\u003cp\u003eThe key to deciding further treatment is the \u003cstrong\u003eclassification of the cancer as either minimally invasive or widely invasive\u003c\/strong\u003e, based on how much the cancer has penetrated its capsule (the fibrous outer covering of the tumor) and whether it has invaded blood vessels. The degree of \u003cstrong\u003evascular invasion (blood vessel involvement)\u003c\/strong\u003e is especially important for predicting outcome.\u003c\/p\u003e\n\n\u003cp\u003eAt Kanaji Thyroid Hospital, the standard protocol is:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003eFor follicular neoplasms classified as \"class III\" with tumor size \u003cstrong\u003eless than 5 cm\u003c\/strong\u003e and no distant metastasis (M0), the hospital typically performs \u003cstrong\u003elobectomy\u003c\/strong\u003e (removal of the thyroid lobe containing the nodule).\u003c\/li\u003e\n  \u003cli\u003ePatients whose postoperative pathology shows \u003cstrong\u003eminimally invasive follicular carcinoma with no vascular invasion\u003c\/strong\u003e (or follicular adenoma, a benign tumor) are followed with: cervical ultrasound once a year; thyroglobulin (Tg) and thyroglobulin antibody (TgAb) blood tests every 6 months; and chest CT scans every 1–2 years (for cancer cases only).\u003c\/li\u003e\n  \u003cli\u003ePatients with \u003cstrong\u003ewidely invasive carcinoma\u003c\/strong\u003e or \u003cstrong\u003eminimally invasive carcinoma with significant vascular invasion\u003c\/strong\u003e who initially had lobectomy are recommended to undergo \u003cstrong\u003ecompletion total thyroidectomy with RAI ablation\u003c\/strong\u003e as a second surgery.\u003c\/li\u003e\n  \u003cli\u003eTotal thyroidectomy is also recommended for patients with \u003cstrong\u003ehighly suspicious widely invasive carcinoma\u003c\/strong\u003e or tumors \u003cstrong\u003e≥5 cm\u003c\/strong\u003e at preoperative diagnosis.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003ePrevious studies from Asian countries have demonstrated that widely invasive carcinoma — especially carcinoma with significant vascular invasion — has a significantly worse prognosis than minimally invasive carcinoma. A study by Ito and colleagues found that the prognostic factors for minimally invasive follicular carcinoma were:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eExtensive vascular invasion\u003c\/strong\u003e (4 or more vessels involved)\u003c\/li\u003e\n  \u003cli\u003e\u003cstrong\u003eAge ≥45 years\u003c\/strong\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003cstrong\u003eTumor size \u0026gt;4 cm\u003c\/strong\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003cstrong\u003eDistant metastasis (M1)\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eEach of these factors independently affected the risk of a patient dying from their cancer.\u003c\/p\u003e\n\n\u003cp\u003eGuidelines differ on when completion total thyroidectomy is appropriate for follicular carcinoma:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eNCCN:\u003c\/strong\u003e Recommends completion total thyroidectomy for extensive vascular invasion\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eATA:\u003c\/strong\u003e Recommends it for all patients except those with tumors smaller than 1 cm\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eBTA:\u003c\/strong\u003e Recommends it when there is evidence of vascular invasion, tumor size \u0026gt;4 cm, or an oxyphilic (Hürthle cell) subtype\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAACE\/AAES:\u003c\/strong\u003e Recommends it for high-risk patients and those with extensive capsular or vascular invasion\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eJSTS\/JAES:\u003c\/strong\u003e Recommends it for widely invasive carcinoma and tumors with poorly differentiated components\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThe authors single out \u003cstrong\u003eoxyphilic (Hürthle) cell carcinoma\u003c\/strong\u003e, a variant of follicular carcinoma, for special mention. While some guidelines recommend total thyroidectomy for this type, \u003cstrong\u003esome Japanese studies suggest that Hürthle cell carcinoma does not have a poorer prognosis than ordinary follicular carcinoma\u003c\/strong\u003e, indicating that treating both types the same way may be acceptable.\u003c\/p\u003e\n\n\u003cp\u003eOn the topic of \u003cstrong\u003epoorly differentiated carcinoma\u003c\/strong\u003e, the WHO classification treats it as an independent histologic type. However, it is not rare for poorly differentiated components to be discovered incidentally during pathological examination of a tumor that was removed under a preoperative diagnosis of a follicular lesion. For these patients, as well as those with insular components, completion total thyroidectomy with RAI ablation is recommended at Kanaji.\u003c\/p\u003e\n\n\u003ch2 id=\"rai\"\u003eRadioactive Iodine Ablation and TSH Suppression: Risks and Benefits\u003c\/h2\u003e\n\n\u003cp\u003eRadioactive iodine (RAI) therapy has been a cornerstone of aggressive thyroid cancer treatment in Western countries. However, even the \u003cstrong\u003eBritish Thyroid Association (BTA)\u003c\/strong\u003e guidelines now question whether RAI ablation is beneficial in \u003cstrong\u003elow-risk\u003c\/strong\u003e patients, and the risk of \u003cstrong\u003esecondary malignancy (development of a new, different cancer)\u003c\/strong\u003e after RAI administration has been raised as a concern.\u003c\/p\u003e\n\n\u003cp\u003eThe authors are careful to note that RAI therapy should be recommended for \u003cstrong\u003ehigh-risk\u003c\/strong\u003e papillary thyroid cancer patients and is essential for treating distant metastases. At Kanaji Hospital, RAI has been used aggressively for high-risk disease and distant metastases since 2005.\u003c\/p\u003e\n\n\u003cp\u003eBut for low-risk patients, the Japanese view is that the risks of RAI — including the potential for a second cancer later in life — may outweigh the benefits, especially when the recurrence rate after limited surgery is as low as 1% in carefully selected patients.\u003c\/p\u003e\n\n\u003ch2 id=\"clinical-implications\"\u003eWhat This Means for Patients\u003c\/h2\u003e\n\n\u003cp\u003eFor patients diagnosed with low-risk thyroid cancer, this review offers several important and reassuring messages:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eNot all thyroid cancers need aggressive treatment.\u003c\/strong\u003e If you have a small papillary cancer (under 2 cm) with no lymph node involvement, hemi-thyroidectomy — or even active observation — may be a reasonable, safe option that preserves your quality of life.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eRemoving the whole thyroid does not protect against lymph node or distant recurrence.\u003c\/strong\u003e The main benefit of total thyroidectomy is preventing recurrence in the remaining thyroid tissue, and it makes RAI therapy easier if needed later.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eYou may be able to avoid lifelong medication.\u003c\/strong\u003e Patients who undergo limited thyroidectomy have a low risk of postoperative hypothyroidism and may not need daily thyroid hormone replacement.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eWatchful waiting is a legitimate option\u003c\/strong\u003e for certain micro-carcinomas (under 1 cm) that lack concerning features.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFollicular cancer is different.\u003c\/strong\u003e If your biopsy cannot rule out follicular carcinoma, your surgeon may recommend lobectomy first, with the decision about a second surgery (completion thyroidectomy) made only after the full pathology report is available.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAsk your doctor about your specific risk category.\u003c\/strong\u003e The high-risk versus low-risk distinction directly determines whether total thyroidectomy, RAI, and TSH suppression are recommended. Understanding your T (tumor), N (node), and M (metastasis) status can help you make an informed decision.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThe authors also note that therapeutic strategies in Western countries and Japan are \u003cstrong\u003emoving closer together\u003c\/strong\u003e. Western guidelines now acknowledge that RAI ablation is questionable in low-risk patients, and Japanese guidelines now accept that total thyroidectomy is preferable for high-risk patients. This convergence reflects a growing international consensus that treatment should be tailored to individual risk rather than applied uniformly.\u003c\/p\u003e\n\n\u003ch2 id=\"limitations\"\u003eStudy Limitations: What This Review Cannot Prove\u003c\/h2\u003e\n\n\u003cp\u003eIt is important to understand the limitations of the evidence presented in this review:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eNo randomized controlled trials:\u003c\/strong\u003e Most information on thyroid cancer outcomes comes from large patient cohorts where therapy was not randomly assigned. This means the level of evidence is generally not high, and direct comparisons between surgery types may be biased.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eConfounded comparisons:\u003c\/strong\u003e In Western studies, most patients who underwent total thyroidectomy also received RAI ablation. These studies may not have genuinely compared total thyroidectomy with limited thyroidectomy as standalone treatments.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSingle-institution experience:\u003c\/strong\u003e The data from Kanaji Thyroid Hospital reflects the practice and outcomes of one specialized Japanese institution, which may not be generalizable to other settings.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eLack of randomized data on lymph node dissection:\u003c\/strong\u003e A prospective randomized controlled trial of prophylactic central lymph node dissection in patients with no clinical node metastasis has not been readily feasible, leaving this question unresolved.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eDiagnostic limitations for follicular cancer:\u003c\/strong\u003e Since follicular carcinoma is usually diagnosed only after surgery, preoperative risk assessment is inherently limited, and some patients may undergo a second operation.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2 id=\"recommendations\"\u003eRecommendations for Patients\u003c\/h2\u003e\n\n\u003cp\u003eBased on this review, here are actionable points patients can discuss with their thyroid care team:\u003c\/p\u003e\n\n\u003col\u003e\n  \u003cli\u003e\n\u003cstrong\u003eGet clear on your risk category.\u003c\/strong\u003e Ask your doctor whether you are low-risk or high-risk, and what your exact tumor size, lymph node status, and pathology features are.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eUnderstand your options for surgery.\u003c\/strong\u003e If you have a low-risk papillary micro-carcinoma, ask whether hemithyroidectomy or even observation could be appropriate rather than automatically proceeding to total thyroidectomy.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAsk about lifelong medication.\u003c\/strong\u003e If you choose limited surgery, inquire about your likelihood of needing thyroid hormone replacement. Many patients who undergo hemi-thyroidectomy retain enough thyroid function to avoid daily medication.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eDiscuss the pros and cons of RAI.\u003c\/strong\u003e For low-risk disease, RAI ablation may offer little benefit and carries a small risk of secondary malignancy. For high-risk disease, it can be life-saving. Your personal risk assessment matters.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eInquire about lymph node dissection.\u003c\/strong\u003e Ask whether prophylactic central or lateral neck dissection is recommended for your situation, and what complications (such as vocal cord paralysis or low calcium) the surgeon anticipates.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eRequest a follow-up plan.\u003c\/strong\u003e If you have low-risk disease, ask about a surveillance plan using ultrasound and thyroglobulin blood tests, with the frequency tailored to your specific cancer type.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eConsider a second opinion.\u003c\/strong\u003e Given the significant differences between guideline recommendations from major organizations, it is reasonable to seek input from a thyroid cancer specialist, particularly one experienced in both aggressive and conservative management strategies.\u003c\/li\u003e\n\u003c\/ol\u003e\n\n\u003cp\u003eThe authors conclude that the goal of treatment should not be to maximize aggressiveness, but to \u003cstrong\u003epreserve quality of life\u003c\/strong\u003e while maintaining excellent cancer outcomes. For lowrisk thyroid cancer patients, less may indeed be more.\u003c\/p\u003e\n\n\u003c!-- ddn:faq:start --\u003e\n\u003ch2 id=\"ddn-faq\"\u003eFrequently Asked Questions\u003c\/h2\u003e\n\u003ch3\u003eIs surgery always needed for a small papillary thyroid cancer?\u003c\/h3\u003e\n\u003cp\u003eNot necessarily. For papillary micro-carcinoma smaller than 1 cm with no lymph node spread, distant metastasis, or significant extrathyroidal extension, active surveillance (watchful waiting) may be an option after thorough discussion with your doctor. Japanese studies show excellent outcomes for low-risk and incidentally detected micro-carcinomas, even without immediate surgery.\u003c\/p\u003e\n\u003ch3\u003eWhat is the difference between total thyroidectomy and hemi-thyroidectomy?\u003c\/h3\u003e\n\u003cp\u003eTotal thyroidectomy removes the entire thyroid gland, while hemi-thyroidectomy removes only half. Total thyroidectomy prevents recurrence in remaining thyroid tissue but requires lifelong hormone replacement and carries higher risks of complications like low calcium or vocal cord paralysis. Limited surgery may avoid lifelong medication and has fewer serious complications, but leaves some risk of recurrence in the remaining tissue.\u003c\/p\u003e\n\u003ch3\u003eWill I need to take thyroid hormone medication for life after surgery?\u003c\/h3\u003e\n\u003cp\u003eIf you have a total thyroidectomy, you will need lifelong L-thyroxine replacement. With a limited thyroidectomy (hemi-thyroidectomy), the risk of postoperative hypothyroidism is low, and many patients keep enough thyroid function to avoid daily medication. Your doctor can estimate your likelihood of needing hormone replacement based on your surgery extent and remaining thyroid function.\u003c\/p\u003e\n\u003ch3\u003eWhat is radioactive iodine ablation and when is it needed?\u003c\/h3\u003e\n\u003cp\u003eRadioactive iodine (RAI) ablation destroys remaining thyroid tissue or cancer cells after surgery. It is essential for treating distant metastases and is recommended for high-risk papillary cancer. For low-risk patients, the benefit is questionable, and it carries a small risk of developing a second cancer later in life. Japanese practice often avoids RAI for low-risk disease.\u003c\/p\u003e\n\u003ch3\u003eHow is follicular thyroid cancer treatment different from papillary cancer?\u003c\/h3\u003e\n\u003cp\u003eFollicular carcinoma is usually diagnosed only after surgery, when the nodule is examined under a microscope. Treatment depends on whether it is minimally invasive or widely invasive. For minimally invasive types with no vascular invasion, lobectomy may be enough. Widely invasive cancers or those with significant blood vessel invasion often require completion total thyroidectomy and RAI ablation.\u003c\/p\u003e\n\u003ch3\u003eWhat are the risks of lymph node dissection during thyroid cancer surgery?\u003c\/h3\u003e\n\u003cp\u003eProphylactic lymph node dissection removes lymph nodes that show no visible cancer. It can reduce the risk of lymph node relapse but does not improve cause-specific survival. The main risks of reoperation in this area are injury to the recurrent-laryngeal nerve, causing vocal cord paralysis, and persistent hypoparathyroidism, causing low calcium levels. Japanese surgeons often recommend dissection during initial surgery to avoid these higher risks later.\u003c\/p\u003e\n\u003ch3\u003eShould I get a second opinion on my thyroid cancer treatment plan?\u003c\/h3\u003e\n\u003cp\u003eYes. Major guidelines from Western and Japanese organizations differ significantly on surgery extent, lymph node dissection, and RAI use. Since treatment can be tailored to your individual risk, it is reasonable to seek input from a thyroid cancer specialist experienced in both aggressive and conservative strategies. A second opinion can help you understand all options for preserving quality of life while maintaining good outcomes.\u003c\/p\u003e\n\u003c!-- ddn:faq:end --\u003e\n\n\u003ch2 id=\"source\"\u003eSource Information\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eOriginal article title:\u003c\/strong\u003e Therapeutic strategy for low-risk thyroid cancer in Kanaji Thyroid Hospital\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eJournal:\u003c\/strong\u003e Endocrine Journal 2014, 61 (1), 1–12 (Review). Submitted July 4, 2013; Accepted September 5, 2013; Released online September 25, 2013.\u003c\/p\u003e\n\n\u003cp\u003eThis patient-friendly article is based on peer-reviewed research and was written to help patients and caregivers understand the findings of the original scientific review. It is not a substitute for professional medical advice. Patients should discuss their individual treatment plans with their healthcare providers.\u003c\/p\u003e","brand":"DiagnosticDetectives.Com","offers":[{"title":"Default Title","offer_id":47458211004572,"sku":null,"price":0.0,"currency_code":"DKK","in_stock":true}],"url":"https:\/\/diagnosticdetectives.dk\/products\/low-risk-thyroid-cancer-why-japanese-doctors-often-choose-less-aggressive-surgery","provider":"DiagnosticDetectives.Com","version":"1.0","type":"link"}